Dibenzoxazepine alpha v integrin receptor antagonist
AssigneeMerck & Co., Inc.
InventorMichael A Patane
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel dibenzoxazepine derivative, its synthesis, and its use as an αv integrin receptor antagonist. More particularly, the compound of the present invention is an antagonist of the integrin receptors αvβ3 and αvβ5 and therefor useful for inhibiting bone resorption, treating and/or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, artheroscietosis, inflammatory arthritis, cancer and metastatic tumor growth.
Claims15
A compound of the structural formula (I):
- 9
- or a pharmaceutically acceptable salt or ester thereof.
The method of claim 40 wherein said organic bisphosphonate or pharmaceutically acceptable salt or ester thereof is alendronate monosodium trihydrate.
Dependencies are inferred from the claim text.